Tagged with disease

Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…

Singapore Recently established in Singapore, Holmusk is a global digital health platform that truly believes in early detection and early intervention. Founder and CEO Nawal Roy describes the underlying motivations behind the company’s founding, the value of positively influencing patient behavior—particularly in tackling chronic diseases—, and how their technology benefits not…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…

Ireland Julie O’Neill, Alexion’s EVP for Global Operations highlights Alexion’s establishment of its Global Supply Chain headquarters in Dublin, Ireland, its investment in Athlone, her thoughts on the opportunities and challenges in the Irish pharmaceutical landscape, and her vision for Alexion. Alexion first established a manufacturing presence in Dublin, Ireland in…

Pharma Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit the patient. Lifestyle related illnesses are a major problem in Mexico, with 13 million people suffering from diabetes and 71…

Healthcare In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings and strategic priorities for fostering inclusive growth and better health outcomes in Mexico, while the Center keeps on strengthening its…

Healthcare Senator Salvador Brito, President of the Health Commission at the Mexican Senate, talks about increasing access to quality healthcare services among the most vulnerable groups in Mexican society, improving and developing life-changing prevention policies, tackling corruption, and investing in health to ensure the country doesn’t compromise its growth perspective. What…

Hungary Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable system.   According to the OECD, life expectancy at birth in Hungary was 75.6 years in 2014, well below the…

Healthcare In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation access and chronic disease prevention, as well as his approach to the upcoming implementation of exchanges of services among the…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However, without the presence of proper mechanisms to arbitrate between regulators and researchers, the sustained growth of this industry may very…